Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Rapid correction of low vitamin D status in nursing home residents 3. 2008 Exclusive Survey—Earnings: Good news for primary care income 4. Medicare pay-for-reporting effort draws fire from frustrated doctors 5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment
Top Ten Searches
rheumatoid arthritis lupus polymyalgia sjogrens fibromyalgia amyloidosis vasculitis urate raynauds myositisYour Article Summary
Positive anti-citrullinated protein antibody status and small joint arthritis are consistent predictors of chronic disease in patients with very early arthritis: results from the NOR-VEAC cohort
Arthritis Research & Therapy, 10/02/09
Mjaavatten MD et al. – Positive ACPA status and small joint arthritis were consistent predictors of three relevant outcomes of chronic arthritis in very early arthritis patients. This consistency supports DMARD prescription as a valid surrogate endpoint for chronic arthritis. Importantly, this surrogate is used in ongoing efforts to develop new diagnostic criteria for early RA.
Methods- Norwegian Very Early Arthritis Cohort (NOR-VEAC) includes adult patients with at least 1 swollen joint of [less than or equal to] 16 weeks duration
- Patients followed for 2 years with comprehensive clinical and laboratory examinations
- Logistic regression analyses performed to determine independent predictors of 3 outcomes: persistent synovitis, prescription of disease-modifying anti-rheumatic drugs (DMARDs), and established clinical RA diagnosis within 1 year
- Of 384 patients eligible for 1 year follow-up (56.3% females, mean (SD) age 45.8 (14.7) years, median (IQR) duration of arthritis 31 (10-62) days), 14.4% were anti-CCP2 positive, and 11.2% were IgM RF positive
- 98 patients had persistent synovitis, 106 had received DMARD treatment during follow-up, while 68 (17.7%) were diagnosed with RA
- Consistent independent predictors across all 3 outcomes were positive anti-citrullinated protein antibody (ACPA) status (odds ratio (OR) 3.2, 5.6 and 19.3), respectively, and small joint arthritis (proximal interphalangeal joint (PIP), metocarpo-phalangeal joint (MCP), and/or metotarso-phalangeal joint (MTP) joint swelling) (OR 1.9, 3.5, and 3.5
Today in Basic Science/Genetics...keeping you current
Receive free subspecialty "5-minute updates" via email
Hepatoprotective effect of TNF-alpha blockade in psoriatic arthritis: A cross-sectional study
Annals of Rheumatic Diseases, 11/09/09
Musculoskeletal manifestations in patients with malignant disease
Clinical Rheumatology, 11/13/09
The relationship between synovial lymphocyte aggregates and the clinical response to infliximab in rheumatoid arthritis: A prospective study
Arthritis & Rheumatism, 11/04/09
Today in Rheumatoid Arthritis...keeping you current
Receive free subspecialty "5-minute updates" via email
Treatment of polymyalgia rheumatica
Archives of Internal Medicine, 11/10/09
Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor [alpha] therapies: Does the risk change with the time since start of treatment?
Arthritis & Rheumatism, 11/05/09
Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study
Arthritis Care and Research , 11/03/09
Sponsor
Article Search
Sponsor


See Latest Articles


